Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).
暂无分享,去创建一个
Leo A. Joyce | E. Sherer | R. Nargund | Akinori Nishimura | Sangita Patel | Jin Wu | Xuanjia Peng | P. Meinke | K. Rickert | D. Olsen | S. Soisson | Sheo B. Singh | Ryuta Kishii | A. Lagrutta | Christopher M. Tan | T. Black | L. Miesel | M. Takei | H. Fukuda | T. Shibata | Y. Fukuda | Xiu-Yang Wang | Jun Lu | D. Kaelin | H. Takano | M. Shibasaki | Robert F. Smith | Changqing Wei | M. Yajima | David E. Kaelin
[1] Sangita Patel,et al. Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents. , 2014, ACS medicinal chemistry letters.
[2] C. Mayer,et al. Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. , 2014, Chemical reviews.
[3] James F Cuff,et al. Systematic approach to conformational sampling for assigning absolute configuration using vibrational circular dichroism. , 2014, Journal of medicinal chemistry.
[4] S. Dabbs,et al. Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases. , 2013, Bioorganic & medicinal chemistry letters.
[5] M. Huband,et al. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. , 2013, Bioorganic & medicinal chemistry letters.
[6] D. Ehmann,et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile. , 2012, Journal of medicinal chemistry.
[7] S. Dabbs,et al. Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases. , 2011, Bioorganic & medicinal chemistry letters.
[8] S. Dabbs,et al. Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases. , 2011, Bioorganic & medicinal chemistry letters.
[9] C. Eyermann,et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity. , 2011, Journal of medicinal chemistry.
[10] Michael R. Mulvey,et al. Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007) , 2009 .
[11] Kristin K. Brown,et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents , 2010, Nature.
[12] K. Coleman,et al. New inhibitors of bacterial topoisomerase GyrA/ParC subunits. , 2009, Current opinion in investigational drugs.
[13] J. Dumas,et al. Chapter 19 Recent Advances in the Inhibition of Bacterial Type II Topoisomerases , 2009 .
[14] D. Platel,et al. Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases , 2008, Antimicrobial Agents and Chemotherapy.
[15] Roberta B Carey,et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.
[16] John J. M. Wiener,et al. Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains. , 2007, Bioorganic & medicinal chemistry letters.
[17] John J. M. Wiener,et al. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis. , 2007, Bioorganic & medicinal chemistry letters.